A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Bin Cao, Yeming Wang, Danning Wen, Wen Liu, Guohui Fan, Lianguo Ruan, Yanping Cai, Ming Wei, Xingwang Li, Jiaan Xia, Nanshan Chen, Ting Yu, Tao Bai, Xuelei Xie, Li Zhang, Caihong Li, Ye Yuan, Hua Chen, Huadong Li, Han-Ping Huang, Shengjing Tu, Fengyun Gong, Ying Liu, Yuan Wei, Chongya Dong, Fei Zhou, Xiaoying Gu, Jiuyang Xu, Yi Zhang, Hui Li, Lianhan Shang, Ke Wang, Kunxia Li, Xia Zhou, Xuan Dong, Zhaohui Qu, Sixia Lu, Xujuan Hu, Shunan Ruan, Shanshan Luo, Jing Wu, Peng Lü, Fang Cheng, Li-hong Pan, Chunmin Jia, Juan Wang, Xia Liu, Shuzhen Wang, Xudong Wu, Jing He, Haiyan Zhan, Fang Qiu, Li Guo, Chaolin Huang, Thomas Jaki, Frederick G. Hayden, Peter Horby, Dingyu Zhang, Chen Wang
New England Journal of Medicine · 2020 · 5,271 citationsOpen access
No retraction on record in OpenAlex.Check Crossref now
Cite this paper
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., Li, X., Xia, J., Chen, N., Xiang, J., Yu, T., Bai, T., Xie, X., Zhang, L., Li, C., … Wang, C. (2020). A trial of Lopinavir–Ritonavir in adults hospitalized with severe Covid-19. New England Journal of Medicine, 382(19), 1787–1799. https://doi.org/10.1056/nejmoa2001282
In text: (Cao et al., 2020)
Ask a question about this research
One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.
Abstract
BACKGROUND: No therapeutics have yet been proven effective for the treatment of severe illness caused by SARS-CoV-2. METHODS: ) of less than 300 mm Hg. Patients were randomly assigned in a 1:1 ratio to receive either lopinavir-ritonavir (400 mg and 100 mg, respectively) twice a day for 14 days, in addition to standard care, or standard care alone. The primary end point was the time to clinical improvement, defined as the time from randomization to either an improvement of two points on a seven-category ordinal scale or discharge from the hospital, whichever came first. RESULTS: A total of 199 patients with laboratory-confirmed SARS-CoV-2 infection underwent randomization; 99 were assigned to the lopinavir-ritonavir group, and 100 to the standard-care group. Treatment with lopinavir-ritonavir was not associated with a difference from standard care in the time to clinical improvement (hazard ratio for clinical improvement, 1.31; 95% confidence interval [CI], 0.95 to 1.80). Mortality at 28 days was similar in the lopinavir-ritonavir group and the standard-care group (19.2% vs. 25.0%; difference, -5.8 percentage points; 95% CI, -17.3 to 5.7). The percentages of patients with detectable viral RNA at various time points were similar. In a modified intention-to-treat analysis, lopinavir-ritonavir led to a median time to clinical improvement that was shorter by 1 day than that observed with standard care (hazard ratio, 1.39; 95% CI, 1.00 to 1.91). Gastrointestinal adverse events were more common in the lopinavir-ritonavir group, but serious adverse events were more common in the standard-care group. Lopinavir-ritonavir treatment was stopped early in 13 patients (13.8%) because of adverse events. CONCLUSIONS: In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir-ritonavir treatment beyond standard care. Future trials in patients with severe illness may help to confirm or exclude the possibility of a treatment benefit. (Funded by Major Projects of National Science and Technology on New Drug Creation and Development and others; Chinese Clinical Trial Register number, ChiCTR2000029308.).
Related papers
- Clinical Characteristics of Coronavirus Disease 2019 in China2020
- A Novel Coronavirus from Patients with Pneumonia in China, 20192020
- A pneumonia outbreak associated with a new coronavirus of probable bat origin2020
- Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China2020
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine2020
Metadata from OpenAlex (CC0). Citations are generated from the published record.